Suppr超能文献

药物透过生物膜:环糊精与静止水层

Drug permeation through biomembranes: cyclodextrins and the unstirred water layer.

作者信息

Loftsson T

机构信息

Faculty of Pharmaceutical Sciences, University of Iceland, Reykjavik, Iceland.

出版信息

Pharmazie. 2012 May;67(5):363-70.

Abstract

Surface of the living epithelia is covered with mucus, a gel-like fluid containing mainly water (90-98%) and mucin (2-5%). This aqueous gel-like matrix forms an unstirred water layer (UWL) creating an aqueous diffusion barrier that hampers drug permeation through mucosal barriers. Frequently, the UWL is the main drug permeation barrier, especially in the case of small-molecular-weight lipophilic drugs. Under such conditions drug permeation can often be enhanced by forming water-soluble drug/cyclodextrin complexes. Cyclodextrins enhance drug delivery through biomembranes by increasing drug permeation through the UWL, that is, by increasing the availability of dissolved drug molecules juxtaposed to the membrane surface. Cyclodextrins only enhance drug permeation when the UWL contributes to the permeation barrier. Cyclodextrins do not enhance drug permeation when the permeation resistance of the UWL is much less than that of the membrane itself. The effect depends also on the physicochemical properties of the drug. As a rule the best results are obtained for lipophilic drugs that are poorly soluble in water, that form water-soluble complexes with cyclodextrins and that possess, as dissolved drug molecules, relatively high permeability through lipophilic biomembranes. It is extremely important to optimize drug vehicles with regard to the amount of cyclodextrin. Too much or too little cyclodextrin will lead to less than optimal drug availability. Good understanding of cyclodextrin complexation and how cyclodextrin affect drug permeation through biomembranes is essential for successful development of cyclodextrin-containing drug formulations.

摘要

活体上皮组织的表面覆盖着黏液,这是一种凝胶状液体,主要包含水(90 - 98%)和黏蛋白(2 - 5%)。这种水性凝胶状基质形成了一个静止水层(UWL),它构成了一个阻碍药物透过黏膜屏障的水性扩散屏障。通常,静止水层是主要的药物渗透屏障,尤其是对于小分子亲脂性药物而言。在这种情况下,通过形成水溶性药物/环糊精复合物,常常可以提高药物的渗透性。环糊精通过增加药物透过静止水层的渗透率来促进药物透过生物膜,也就是说,通过增加与膜表面相邻的溶解药物分子的可利用性来实现。只有当静止水层对渗透屏障有贡献时,环糊精才会增强药物的渗透性。当静止水层的渗透阻力远小于膜本身的渗透阻力时,环糊精不会增强药物的渗透性。这种效果还取决于药物的物理化学性质。一般来说,对于在水中溶解度低、能与环糊精形成水溶性复合物且作为溶解药物分子时通过亲脂性生物膜具有相对较高渗透率的亲脂性药物,能获得最佳效果。关于环糊精的用量来优化药物载体极其重要。环糊精过多或过少都会导致药物可利用性达不到最佳。深入了解环糊精络合作用以及环糊精如何影响药物透过生物膜,对于成功开发含环糊精的药物制剂至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验